Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1626
This examiner grants 61% of resolved cases
Ashli Ariana Chicks is an examiner in Tech Center 1600 and Art Unit 1626, with 94 resolved cases. The allowance rate is 60.6%, which is the baseline success rate for applicants. The interview lift is 50.3%, indicating that interviews are a very effective tool for increasing the probability of allowance over the 60.6% baseline. This suggests that direct communication is a primary strategy for success with this examiner.
The median days to allowance is 1222, which is the typical duration for the 94 resolved cases. Given the 50.3% interview lift, practitioners should prioritize interviews to navigate the 1222-day timeline more successfully. The 60.6% allowance rate in Art Unit 1626 indicates that while the process is lengthy, interviews provide a strong path to a positive outcome. Attorneys can use the 1222-day median and 50.3% lift to develop a targeted strategy in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18706869 | COMPOSITIONS AND METHODS FOR TREATING CANCER VIA PTP1B INHIBITION | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18741322 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | The Regents of the University of California |
| 18897912 | ORGANIC COMPOUND, ORGANIC SEMICONDUCTOR DEVICE, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE | Non-Final OA | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. |
| 18694690 | FUNGICIDAL COMPOSITIONS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18893201 | FORMULATIONS OF ANTIVIRAL COMPOUNDS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18015856 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | Non-Final OA | NOVARTIS PHARMA AG |
| 18902141 | COMPOSITION AND METHOD FOR TREATING FUNGAL SKIN CONDITIONS AND INFLAMMATION | Non-Final OA | CMPD Licensing, LLC |
| 17414697 | CANCER TREATMENTS | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18870598 | SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS | Non-Final OA | AstraZeneca AB |
| 18834185 | ANTAGONIST OF ADENOSINE RECEPTORS | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18260711 | PROTECTED ALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES | Non-Final OA | CAAMTECH, INC. |
| 18253846 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | Non-Final OA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| 18053332 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | Non-Final OA | SERVIER PHARMACEUTICALS LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy